 Connection
Charles Dinarello to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Charles Dinarello has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.320 |
|
|
|
-
Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010 Aug; 17(4):314-21.
Score: 0.115
-
Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol. 2019 12; 19(12):734-746.
Score: 0.054
-
Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014 Dec 16; 20 Suppl 1:S43-58.
Score: 0.039
-
Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P, Boekschoten MV, Müller M, Kersten S, Li S, Kim S, Eini H, Lewis EC, Joosten LA, Tilg H, Netea MG, Tack CJ, Dinarello CA, Stienstra R. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014 Sep 03; 5:4711.
Score: 0.038
-
Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, Solinger AM, Mandrup-Poulsen T, Dinarello CA, Donath MY. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012 Aug; 35(8):1654-62.
Score: 0.033
-
Dinarello CA. Blocking interleukin-1ß in acute and chronic autoinflammatory diseases. J Intern Med. 2011 Jan; 269(1):16-28.
Score: 0.030
-
Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015 Oct; 75(2):280-90.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|